RESERPINE AND HYDROCHLOROTHIAZIDE-50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Reserpine And Hydrochlorothiazide-50, and what generic alternatives are available?
Reserpine And Hydrochlorothiazide-50 is a drug marketed by West Ward and is included in one NDA.
The generic ingredient in RESERPINE AND HYDROCHLOROTHIAZIDE-50 is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RESERPINE AND HYDROCHLOROTHIAZIDE-50?
- What are the global sales for RESERPINE AND HYDROCHLOROTHIAZIDE-50?
- What is Average Wholesale Price for RESERPINE AND HYDROCHLOROTHIAZIDE-50?
Summary for RESERPINE AND HYDROCHLOROTHIAZIDE-50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 2 |
| DailyMed Link: | RESERPINE AND HYDROCHLOROTHIAZIDE-50 at DailyMed |
Recent Clinical Trials for RESERPINE AND HYDROCHLOROTHIAZIDE-50
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| West China Hospital | Phase 4 |
| US Department of Veterans Affairs | |
| VA Office of Research and Development |
See all RESERPINE AND HYDROCHLOROTHIAZIDE-50 clinical trials
US Patents and Regulatory Information for RESERPINE AND HYDROCHLOROTHIAZIDE-50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| West Ward | RESERPINE AND HYDROCHLOROTHIAZIDE-50 | hydrochlorothiazide; reserpine | TABLET;ORAL | 088189-001 | May 10, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

